...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in drug safety. >Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand
【24h】

Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand

机译：QT间歇性抗精神病药的共同作用，泰国潜在互动药物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The US FDA has designated pimozide, thioridazine, and ziprasidone as contraindicated for patients at risk of QT interval prolongation, and assigned haloperidol, olanzapine, paliperidone, quetiapine, and risperidone as associated with a significant risk of QT prolongation. This study aimed to examine trends and hospital variations in concomitant prescribing among these eight selected antipsychotics, and coprescription with interacting drugs known to increase QT prolongation risk. Data on outpatient antipsychotic prescriptions during 2012-2015 were obtained from 16 general hospitals and 10 university hospitals nationwide. A time-series analysis was used for estimating trends in coprescription that led to drug interactions. Coprescribing among the eight antipsychotics ranged from 7.5% for quetiapine to 33.1% for thioridazine. The rate of coprescription with contraindicated interacting drugs was 9.7% for thioridazine and 21.9% for pimozide, and increased by 1.1 and 1.4?percentage points (% pt.) yearly for thioridazine in general and university hospitals, respectively. Coprescribing with interacting drugs with precautions was 2.8% for quetiapine, 7.4% for ziprasidone, and 27.9% for risperidone; these percentages increased yearly by 1.7%?pt. for ziprasidone and 2.6%?pt. for risperidone in general hospitals, as well as by 1.0%?pt. for risperidone in university hospitals. The median proportion of patients exposed to a QT-prolonging interaction was 12.3% across hospitals (interquartile range, 9.9-19.5%). Wide interhospital variation was found in percentages of drug interactions among patients receiving thioridazine, ziprasidone, paliperidone, or olanzapine in general hospitals, and among patients receiving paliperidone or pimozide in university hospitals. Coprescription of antipsychotics with interacting drugs that could increase the risk of QT prolongation was common in Thailand, and thioridazine, ziprasidone, and risperidone showed increasing trends. We urge the incorporation of a unified list of QT-prolonging antipsychotics and interacting drugs into a computerized drug interaction warning system, and existing national rational drug use campaigns should cover this important issue.
机译：美国FDA已经指定了QT间隔延长风险，并指定氟哌啶醇，奥洲氮杂醇，奥氮化萘酚，喹啉酮，喹啉酮与QT延长风险相关的患者的患者。本研究旨在审查这八种选定的抗精神病药的伴随处方的趋势和医院变化，并用众所周知的药物进行共同鉴定，以提高QT延长风险。 2012 - 2015年间门诊抗精神病式处方的数据是从全国16个综合医院和10家大学医院获得的。时间序列分析用于估算导致药物相互作用的共同体中的趋势。八个抗精神病药之间的共同封装从喹唑嗪的喹硫碱的7.5％从7.5％到33.1％。脱噻嗪的共同鉴定率为9.7％，均为嘧啶的21.9％，分别增加1.1和1.4？百分点（％pt）分别在一般和大学医院的硫嗪的年度分钟（％pt。）。喹硫酮的喹硫酮与预防措施的互动药物共同封装为2.8％，齐己酮为7.4％，蓖麻籽酮为27.9％;这些百分比每年增加1.7％？PT。对于Ziprasidone和2.6％？PT。对于普通医院的Risperidone，以及1.0％？PT。在大学医院的Risperidone。医院（四分位数范围，9.9-19.5％），暴露于近QT延长互动的患者的中位数比例为12.3％。在综合医院接受硫嗪，齐拉西酮，Paliperidone或Olanzapine的患者的药物相互作用百分比中发现了宽的互康变异，以及在大学医院接受Paliperidone或Pimozide的患者。抗精神病药与可增加QT延长风险的抗精神病药术共同鉴定在泰国，硫吡嗪，齐普拉西酮和立率呈增加趋势。我们敦促将统一的QT-延长抗精神病药列表纳入统一列表，并将药物互动成计算机化的药物互动警告系统，现有的国家理性药物使用竞选活动应涵盖这一重要问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号